WisdomTree International MidCap Dividend Fund DIM
87.97 USD +2.13 (+2.48%)
At closeNov 4, 2026, 4:10 PM EST
87.97 0.00 0.00%
After hours · Nov 4, 4:10 PM ET
87.93 Day range 88.00
75.63 52-week range 90.63
- YTD
- +9.19%
- 1 year
- +15.02%
- Market cap
- 158.76M
- EPS (ttm)
- 5.96
- P/E ratio
- 14.76
- YTD return
- +9.19%
- 1-year return
- +15.02%
- Volume
- 2.47K
- Avg volume
- 3.59K
- Open
- 87.93
- Previous close
- 85.84
- Day's range
- 87.93 – 88.00
- 52-week range
- 75.63 – 90.63
1m +0.03 (+0.03%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 63.06
- 200-day average
- 63.00
About WisdomTree International MidCap Dividend Fund
The fund normally invests at least 95% of its total assets (exclusive of collateral held from securities lending) in constituent securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such constituent securities. The index is a fundamentally weighted index that is comprised of the mid-capitalization segment of the dividend-paying market in the industrialized world outside the U.S. and Canada. The fund is non-diversified.
News
A Deeper Look At Our International Dividend Index Rebalance
10 Mid-Cap ETFs to Buy for Next Decade
Nine-month Figures For 2019: Sartorius Stedim Biotech Reports Double-digit Sales Growth
Nine-Month Figures for 2018: Sartorius Stedim Biotech Continues to
Grow by Double Digits
Business Figures for the First Half of 2018: Sartorius Stedim Biotech
Records Double-Digit Growth in Sales and Profit
First-Quarter Figures: Sartorius Stedim Biotech off to a Dynamic
Start into 2018
Preliminary Results for 2017: Sartorius Stedim Biotech Grows in
Revenue and Earnings – Positive Outlook for 2018
Sartorius Stedim Biotech: Growth dynamics temporarily dampened;
continued strong mid-term perspectives
Sartorius Stedim Biotech S.A.: 2017 First-Half Figures
First-Quarter Figures: Sartorius Stedim Biotech Off to a Good Start
in 2017
Your note
Sign in to keep a note on DIM — it syncs with the Stock Master app.
